METRODORA Intent to Use Trademark - Multisystem Disorder Pharmaceuticals
Summary
USPTO received an Intent to Use trademark application TM97023419 from METRODORA for pharmaceutical preparations in Class 5 covering treatments for complex or rare multisystem disorders. The application includes pharmaceuticals for conditions such as autoimmune disorders, neurological disorders, gastrointestinal disorders, and pain management. No regulatory obligations or compliance deadlines are associated with this trademark filing.
What changed
METRODORA filed an Intent to Use trademark application (TM97023419) with USPTO on September 12, 2021, seeking registration for the METRODORA mark in connection with pharmaceutical products for treating complex multisystem disorders including autoimmune, neurological, gastrointestinal, and pain-related conditions. The application covers prescription diets and nutritional supplements provided by prescription for these conditions.
No immediate compliance action is required from pharmaceutical companies or other regulated entities. Trademark applications proceed through USPTO examination, publication for opposition, and potential registration phases. Trademark applicants should monitor application status and respond to any USPTO Office Actions. Third parties who believe the mark may cause confusion may file opposition during the publication period.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
← USPTO Trademark Applications
METRODORA
Intent to Use TM97023419 Kind: intenttouse Apr 02, 2026
Abstract
Pharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; pharmaceutical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; therapeutic pharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; medical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; prescription diets, namely, dietetic foods and nutritional and dietary supplements provided by prescription for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries
Filing Date
2021-09-12
Named provisions
Related changes
Get daily alerts for USPTO Trademarks - Pharmaceuticals (Class 005)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Trademarks - Pharmaceuticals (Class 005) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.